Project Alert

Biopharma PTC Therapeutics has signed a seven-year lease for over 100,000 square feet at the New Jersey Center for Excellence campus in Bridgewater. The New Jersey-based company will relocate from its current site in South Plainfield and occupy three floors spanning a total of 101,500 square feet at the 48-acre research and development campus, at 1021 US 202/206. The campus comprises eight buildings, primarily laboratory or research and development facilities, and is anchored by nutritional health company Nestle Health Sciences, chemicals firm Ashland and drug producer Amneal Pharmaceuticals. Learn More

Plans are moving forward for Selkirk Pharma's $30 million manufacturing facility on the West Plains near Spokane, Washington The company, a contract manufacturing biopharma startup, filed an environmental review for the project with the Washington state Department of Ecology last week. The company intends to build a 65,000-square-foot manufacturing facility at 9110 W. Granite Ave. in the Pacific Northwest Technology Park, according to an application filed with the city of Spokane. Construction is expected to begin in August and is slated for completion in December 2021, according to the environmental review. Spokane-based Bernardo|Willis Architects is designing the project. Learn More

A&C has recently expanded its footprint into Europe with the opening of A&C Bio Buffer Ltd, a new state-of-the-art GMP manufacturing facility in Ireland. The Irish facility is ISO 9001:2015 certified and is dedicated to GMP manufacturing of biological buffers, process solutions, cleaning solutions, chemical blends, WFI (water for injection) and GMP raw material repacking. A&C Bio Buffer is the only company in Ireland to manufacture biological buffers with water for injection. The new Irish production site is another significant addition to the A&C Group, which currently has two GMP manufacturing plants in North America. Learn More

A 65,269-square-foot industrial building in the Conejo Valley has sold for $8.1 million, with the new owner looking to turn it into biotech labs. The warehouse, located at 1300 Rancho Conejo Blvd. in Thousand Oaks, sits on 5 acres. The new owner, Alexandria Real Estate Equities, is understood to be planning to redevelop the site to house biotechnology labs to accommodate the rising number of industry users in Ventura County. Alert readers will recall a number of stories in recent months detailing growth in the region particularly among smaller, fast growing biotech companies seeking to replicate the success of local success story Amgen. Learn More

FUJIFILM Diosynth Biotechnologies held a ground breaking ceremony this week signalling commencement of construction of the company's new BioCampus at its Billingham, UK location. This BioCampus development will include the construction of 42,000 square foot purpose-built office accommodation and visitor center in addition to making ready the land for potential expansion that could include additional research and development laboratories and new manufacturing facilities. The construction is expected to be completed by March 2021. Learn More

Bora Pharmaceuticals and GSK have entered into an agreement under which Bora will acquire GSK's Mississauga, Ontario (Canada) facility. The GSK facility produces approximately 50 different products for over 100 markets worldwide and employs approximately 400 skilled manufacturing staff who will be invited to join Bora as part of the transaction. Bora will continue to manufacture, under contract, the existing GSK product line for a minimum of five years. GSK employees in the Pharmaceuticals and Consumer Healthcare commercial businesses, who currently work in office space at the Mississauga site will move to new locations within an agreed timeframe following the close of the transaction. Learn More

Amicus Therapeutics will officially unveil its $25 million global research and gene therapy center in Philadelphia on Thursday of this week. The center, whose laboratory and office space were designed by CRB, was secured by Amicus last year. Alert readers will recall that Amicus entered into a 10-year lease deal for roughly 75,000 square feet spread across the top three floors at 3675 Market Street in University City. The location is ideal for amongst other things its proximity to the company's major gene therapy partner: the University of Pennsylvania with whom Amicus recently expanded its working relationship. Learn More

The cost of the new global headquarters of Britain's biggest drugs company has risen to about $1.3 billion (£1 billion), more than three times the original estimate. Astrazeneca had planned to spend $425 million (£330 million) on the Cambridge site, which will also be its research and development center, but the costs have jumped for a third time to make it one of the most expensive corporate buildings in the country. It is also way behind schedule - it was due to open in 2016. The latest cost estimate comes after a review by Mace, which replaced Skanska as construction manager in 2018. Astrazeneca moved from Alderley Park in Cheshire to the new site on the biomedical campus in the south of Cambridge seven years ago. Learn More

Amunix has made public plans to combine the $73 million generated from its financing round with the $40 million upfront payment received from Roche to advance its lead drug candidate, AMX-818. As part of its plans the company will relocate from Mountain View to South San Francisco, California later this year. Amunix is aiming at developing T-cells to attack and destroy solid tumors without the toxic reactions that have been observed, as well as immunogenicity limitations. No word yet on just where in South San Francisco the company will be located, but the close ties to Roche would suggest the Oyster Point area. Learn More

Exicure has leased 30,000 sq. ft. in a 120,000 sq. ft. building known as The Labs at 2430 N. Halstead in Lincoln Park and plans to move in this Summer. The building is owned by developer Sterling Bay, which is preparing to undertake construction of the $6 billion Lincoln Yards project roughly a mile away. It is expected that biopharma firms will play a prominent role in the 55-acre development as the first phase of construction is expected to include 350,000-400,000 sq. ft. of biopharma research and office space. The total build out of the site has approval to be as much as 14.5 million sq. ft. of mixed use. Learn More

FUJIFILM Cellular Dynamics will begin operations at its new cGMP-compliant iPSC production facility in Madison, WI this week. The new Innovation Facility for Advanced Cell Therapy (i-FACT), will house development and manufacture of iPSCs for therapeutic applications. The i-FACT will enable FCDI to accelerate the development of its own pipeline of regenerative medicine therapies using iPSCs, as well as serve as a CDMO of IPSCs and iPSC-derived differentiated cells. The $21 million, 32,000 sq.-ft. facility features four development labs and three cGMP suites for in-house therapeutic development and for collaboration with other companies. The facility is designed to enable each suite to manufacture a different product to offer scale-up and scale-out biomanufacturing ability to facilitate various batch sizes. Learn More

San Jose BioCube, a long-established life sciences incubator, has announced the availability of 15 move-in-ready wet labs designed for high-potential life sciences startups. Dubbed "BioCube North," the incubator is housed on the ground floor of the Q Bay Center, the 112,232-square-foot facility at 160 East Tasman Drive in San Jose, California. Launching in March, BioCube North's labs will offer over 5,000 square feet of shared space where life-sciences startups have the appropriate plumbing, ventilation, refrigeration and equipment, together with BioCube's global standard of facility management and client care, to grow their businesses. Learn More

FUJIFILM Diosynth Biotechnologies broke ground this week on its North Carolina facility expansion project. The 31,778 square foot addition includes the expansion of its cell culture and microbial manufacturing trains through the addition of new recover and purification suites. The North Carolina site will increase its cell culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50%. A new receiving warehouse is also included in the project. FDB expects that the increased production capacity will be ready for cGMP manufacture by mid-2021. Learn More

WuXi Vaccines has announced that it has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion. As part of the deal WuXi will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC). The facility will be dedicated to manufacture one of its partner's vaccine products for the global market. The new facility is expected to be operational in 2022. Learn More

Audentes Therapeutics, a gene therapy developer recently bought by Astellas, will invest about $110 million to build a manufacturing plant in North Carolina, joining a growing list of drugmakers choosing to locate new drug production facilities in the state. For Audentes, the decision to invest in a new facility emerged from planning for when the biotech outgrows the capacity it currently has in a South San Francisco plant, according to Donald Wuchterl, the company's head of technical operations. Audentes cast a wide net for where to place its newest facility, eventually choosing a small town southwest of Raleigh already home to one gene therapy plant, which Pfizer's now spending $500 million to expand. Learn More

Grifols has announced the signing of a non-binding agreement with Saudi Arabia's sovereign wealth fund to help the country produce blood plasma-derived medicines. Barcelona based Grifols and the Saudi Public Investment Fund (PIF) have agreed in principle to create a joint venture that will develop plasma collection centers and production facilities, including a fractionation and a purification facility in Saudi Arabia. Grifols will provide knowledge and intellectual property, and will also supply plasma medicines to Saudi Arabia until the joint venture becomes capable of producing them. No financial details or stakes in the planned joint venture have been made public as of this writing. Learn More

PBSC, the cleanroom components manufacturer based in England, has opened new offices in Massachusetts, United States. The office will be spearheaded by Stephen Grant. Established in 1987, PBSC specializes in manufacturing products for cleanroom, high containment and material decontamination areas. The company boasts an extensive product range, bespoke designs and assembly capabilities. PBSC Inc will be found at Braintree, Massachusetts, the team will work hand-in-hand with its counterpart in the UK. Learn More

WuXi Biologics has awarded Ardmac the roughly 160,000 square feet (15,000 square meters) of specialist cleanroom construction on their purpose-built facility at Mullagharlin in Dundalk, Co. Louth. The CDMO's facility has been described in reports on the project as the "Factory of the Future". Ardmac is expected to employ over 200 people over the course of the project at Dundalk, with completion expected by 2021. The project will be deployed using Ardmac's SMART delivery model, implementing lean principles and techniques coupled with the implementation of the latest digital field collaboration software to support the build efficiently. Learn More

Novo Nordisk has announced plans to invest roughly $115 million (DKK 800 million) in upgrading and expanding the facilities at its production site in Kalundborg, Denmark. The existing facilities currently manufacture a range of products for diabetes treatment and will be rebuilt and expanded to allow for future production of these products as well as the next generation of diabetes products. Established in 1969, the site covers a total area of 12.9 million sq. ft. (1.2 million sq. m) and employs more than 3,000 people. Besides diabetes a number of other biopharmaceuticals are produced at the site. The projects are expected to be completed in 2022. Learn More

AstraZeneca has announced that it will invest $200 million into the company's manufacturing facility in North Ryde, Sydney. The investment follows $100 million announced in 2017 and will go towards increasing the facility's production capabilities, creating 250 jobs and increasing exports to $4.4bn over the next four years. The local North Ryde facility is among the most digitized and innovative in the company's global network, delivering medicines to millions of patients who need them in Australia, the Asia-Pacific region and other global markets. Learn More

Exelixis has leased a yet-to-be-built office building at 1951 Harbor Way in Alameda, California that, when constructed and complete, will total 220,000 square feet. The biotech currently occupies a 64,000-square-foot building at 1851 Harbor Bay Parkway. Development of the new headquarters, which could have capacity for as many as 1,100 employees, is expected to begin this summer. However, as of this writing, a precise timeline for completion has not yet been made public. Learn More

Takeda has confirmed it is looking for a buyer for its operations in Dunboyne, Co Meath. The site employs some 200 and Takeda says no redundancies are planned. In a statement, the company said: "As a result of Takeda's acquisition of Shire last year, and subsequent integration, Takeda has decided to divest its biologics facility in Dunboyne." The site was the last major investment made by Shire before it was acquired by Takeda last year. The company invested $415 million (€375 million) in setting up a new biologics manufacturing plant on its 120-acre site in Dunboyne. The company says day-to-day operations at the facility will continue "as we complete commissioning and validation of the facility"... Learn More

Vigene Biosciences has opened its new research facility in Rockville, Maryland. The opening of a new laboratory at 5 Research Court - near Interstate-270's Shady Grove Road exit - significantly increases the biotech's Rockville footprint, adding 51,000 square feet to its existing 20,000 square feet at a separate facility nearby. The project cost more than $20 million, according to Vigene. The company, which partners with therapeutic developers to lower the cost of manufacturing, will now use both facilities for research, development and production. The company first moved into the space, its new global headquarters, in October, after shutting down its former Rockville HQ. Learn More

CDMO Piramal Pharma Solutions has announced plans to expand its Aurora facility in Canada with the addition of a new state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients (APIs). A total investment of $19 million (CAD$25M) will be invested at the site. The planned expansion will add roughly 10,500 sq. ft. of new manufacturing space to the existing facility and equip it with two new reactor suites as well as a dedicated filter dryer room and a portable filter dryer. The project is expected to be completed and the site operating by April 30th, 2021. Learn More

Krystal Biotech has broken ground on its new biologics manufacturing facility near Pittsburgh, Pennsylvania. The 100,000 sq. ft. building in the Airport Corridor will be primarily used to make the company's gene therapy medicines for rare skin problems. Krystal CEO Krish Krishnan said the building is expected to cost between $70 million and $90 million with a target completion date of 15 months. Staffing for the new building is expected to create 70 initial new jobs with more expected to be added when the site is fully operational. In the meantime, the company will continue to operate from its South Side facilities which include a 4,500 sq. ft. lab. Learn More

Merck KGaA has announced an investment of $275 million (€250 million) in a new facility in Corsier-sur-Vevey, Switzerland - the Merck Biotech Development Center - dedicated to biotech development and manufacturing. Located near Merck's current biotech commercial manufacturing site the Center will bring together research and manufacturing. The facility will consist of a building providing a total of 169,000 sq. ft. (15,700 sqm) of development space. Equipped with continuous manufacturing and laboratory automation, the construction of the Biotech Development Center is expected to be completed in 2021 with the site validated and fully operational by the end of 2022. Learn More

The Center for Breakthrough Medicines, a newly formed CDMO whose mandate is to facilitate patient access to critically needed cell and gene therapies, has signed a long-term lease for 680,000 square feet at The Discovery Labs site in King of Prussia, Pennsylvania. The site, a former GSK campus, will be home to an estimated 2,000 scientists, manufacturing experts, lab technicians and support staff. Plans for the site include 75-100 suites distributed among roughly 26 interconnected buildings. According to published reports, the site is expected to be partially operational by years end and fully operational in 2021. Learn More

GE Healthcare Life Sciences is building a new 79,000 sq. ft. (7,360 sqm) facility in Grens, Switzerland. The site, located in the new Signy Park will be equipped for the manufacture of single-use kits for the Sepax and Sefia cell processing systems. In addition to its manufacturing capabilities, the new site will house a Center of Excellence that will feature advanced cell and gene therapy manufacturing facilities and will also support a growing Research & Development team and other subject matter experts. The facility will meet global regulatory requirements and is expected to be fully operational in 2022. Learn More

AstraZeneca has announced plans for a five-year, $500 million investment in France. The details of the investment includes $230 million to finance the expansion and modernization of the company's development and manufacturing site in Dunkirk. This will include the building of three assembly lines and two packaging lines at the site. With an additional $275 million slated for investment in research and development efforts at company sites across France. Finally, an amount of $15 million has been set aside for the creation of a European Innovation Hub in Paris. Learn More

Eli Lilly and Company has made public plans to build a $470 million dollar biopharma manufacturing plant, creating more than 460 high-paying jobs, in Durham, North Carolina. The decision to build in North Carolina comes after the company conducted a nationwide search for a location for the new plant. Indiana, Pennsylvania and North Carolina were the finalists. According to published reports the new facility will produce injectable products and delivery devices. Alert readers will recall that late last year Lilly announced plans to invest $400 million into its manufacturing facilities at the Lilly Technology Center in Indianapolis. Learn More

Celltrion has made public details of its previously announced 120,000 liter biologics manufacturing facility. The facility, to be built in Wuhan, China, promises to be the country's biggest biologics plant, far exceeding the capacity of the current 5,000 liters facility that serves as China's largest. The site is expected to provide Celltrion with a location from which to both develop and manufacture its own biologics for the Chinese market. According to published reports, plans for the site include the role of CMO for local biotechs. Groundbreaking for the site is planned for this Spring and funding is slated through 2025. 

Leading South Korean biosimilar manufacturer Celltrion has made public plans to build a plant in China in a move to directly advance into the world's second-largest biopharmaceutical market, its chief said. "We are in the final stage of signing a contract with the Chinese government. We will soon announce details of the plant," Chairman Seo Jung-jin said during the annual J.P. Morgan Healthcare Conference. The company's business roadmap centers on building a plant with a production capacity of 120,000 liters in China to boost capacity amid rising demand. According to Celltrion, the planned production facility will be the largest of its kind in China. Learn More

Just - Evotec Biologics has initiated construction of a 130,000 sq. ft. late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington. Construction on the greenfield site, located in Redmond Ridge Business Park, is expected to be completed by late 2020 and operational in the first quarter of 2021. The facility will contain manufacturing pods for implementing intensified fed-batch or continuous processing up to 1,000 L scale, with the capability of manufacturing metric tons of drug substance. Also included are supporting quality labs and process development labs. Learn More

Kite Pharma, a subsidiary of Gilead Sciences, has made public plans to push back by roughly one year the planned achievement of commercial production at its site in Urbana. Alert readers will recall that the company is constructing a new 279,000-square-foot plant in Urbana, Maryland after purchasing the 20 acre property on Bennett Creek Blvd in November 2018 for $7.5 million. The project delay is being attributed to building enhancements. It is understood that the new site will manufacture Kite's producers of chimeric antigen receptor T (CAR T) therapies, including Yescarta, which is Kite Pharma's commercially available CAR T therapy. Learn More

Janssen has announced a significant investment to expand its R&D presence and capabilities in the San Francisco Bay Area. This investment will support the leasing and construction of a state-of-the-art R&D facility in the global innovation center of South San Francisco, CA. Janssen executed the lease at The Shore at Sierra Point in Brisbane, CA. Janssen personnel at this new facility will focus on infectious and retinal diseases, data science and emerging modalities within discovery, product development and supply. The expanded facility is projected to more than double Janssen's presence in South San Francisco and is anticipated to be fully operational in 2022, upon completion of construction. Learn More

G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, this week unveiled another facility expansion, adding to the company's 200,000 sq. ft. manufacturing site in College Station, TX. The new facility, opening January 2020, consists of 25,000 sq. ft. of manufacturing space dedicated to POD architectural, mechanical, electrical and automation fit out. This development completes Phase 4 of G-CON's growth at its manufacturing site in Texas. G-CON recently announced another 25,000 sq. ft. facility expansion for superstructures, doubling the company's superstructure capacity. Learn More

Rooster Bio has made public plans to expand its site in Frederick, Maryland by roughly 30%, adding an additional 5,000 sq. ft. to its existing 15,500 sq. ft. footprint. This is the second expansion of the site since 2019. The biopharma is focused on developing and manufacturing human adult stem cells and stem cell-based products, supplying human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems. The driver behind this expansion is increasing global demand for the company's products and services. According to published reports, this expansion will include additional jobs. Learn More

Bristol-Myers Squibb announced this week that it has completed its previously announced divestment of its 208,000 sq. ft. oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to Catalent. The Anagni facility manufactures and packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics. The divestiture is part of Bristol-Myers Squibb's strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline. Learn More

Joinn Biologics has secured $60 million in Series A financing to help it build a comprehensive biopharma service platform designed to enable the company to achieve recognition as a leading CDMO for biologics globally. To that end, the company had made public plans to construct a biologics manufacturing facility equipped with 100,000-liters of capacity in China. Additionally, the company is understood to be planning expansion at its operations in the U.S. Alert readers will recall that Joinn, founded in 2018, currently has 2,000 liters of capacity in Richmond, California and 1,400 liters of capacity currently in place in China. Learn More

AGC Biologics is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany. The expansion of the site includes a pDNA manufacturing process improvement project that enables the extension of the offer in hosts and plasmids (low and high copy pDNA expression systems) via a large toolbox in process development with scales of 1L to 10L for High Quality pDNA. These processes can easily be scaled up to fit into the established 50L, 100L, 500L or 1000L GMP manufacturing. This expanded site joins AGC microbial facilities in Heidelberg (Germany), Copenhagen (Denmark) and Chiba (Japan), and soon an additional microbial facility in Seattle (United States). Learn More

Symbiosis Pharmaceutical Services has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%.  The company has invested more than $1.9 million in the expansion of its Stirling site, doubling its current footprint with an additional 8,000 sq.-ft. of space to house administrative, management and operational teams, as well as the expansion of its manufacturing space and its supporting services infrastructure. The new operational area also provides additional capacity for GMP-compliant manufacturing services for supply chain management, additional temperature-controlled storage, and the company's first automated labelling and packaging equipment. Learn More

Wuxi Biologics have been given the go ahead for phase two of their site at the IDA Ireland Dundalk Science and Technology Park at Mullagharlin. This will include construction of a new three-story, 167,000 sq. ft. vaccine production facility. Additionally, a 95,000 sq. ft., four-story lab and administration building will also be built as will a two-story, 9,000 sq. ft., modular support lab. Alert readers will recall that last month Wuxi announced plans to build a $240 million vaccine production facility on the new campus. This comes amid reports that Wuxi intends to also invest heavily in microbial fermentation capacity at its site in China. Learn More

The largest biotechnology incubator of its kind in New York City, BioLabs@NYULangone, opened this week at 180 Varick Street in Manhattan. The 50,000 sq. ft. of newly renovated and fully equipped laboratory and office space will eventually be home to more than 35 early -stage biotechnology and life science companies. Currently, 22 biotech companies reside in the space. Companies selected for BioLabs@NYULangone will start with a package of tailored laboratory equipment and supplies. BioLabs staff will provide educational programming and operational support, enabling startups to focus on science and innovation, and ultimately move more quickly into their own spaces. Learn More

CatSci, a contract research organization (CRO), is furthering its expansion strategy to deliver tailored chemistry services to support the Chemistry, Manufacturing and Controls (CMC) demands of its global biopharma customers. The expansion includes the addition of two new laboratories. These are new facilities that have been refurbished to enable CatSci to scale out its best-in-class process research and development operations for API synthesis and manufacturing. This is in addition to laboratories that have been launched this year, which include a scale-up facility, 20L vessels for material supply and analytical facilities for non-GMP analytical development. Learn More

Merck will invest $57 million to expand vaccine manufacturing capabilities at its site in Wilson, North Carolina for production of RotaTeq which protects babies from rotavirus. "Merck is delighted to announce its second significant investment at our Wilson plant in less than a year," said Sanat Chattopadhyay, Executive Vice President and President, Merck Manufacturing Division. This latest commitment will enable us to introduce a new and innovative filling and packaging technology to assist in the production of our important RotaTeq vaccine. We appreciate all the support we've received for this project from Governor Cooper, Secretary Copeland and his staff, and from Wilson County." Learn More

BioMed Realty has inked a 240,000-square-foot lease with Amgen at its Gateway of Pacific campus in South San Francisco. The new long-term deal at the 1.3-million-square-foot life science campus that is currently under construction will house Amgen's Bay Area scientists and employees focused on cardiometabolic, inflammation and oncology research. BioMed also recently signed leases with leading innovation companies, including Zymergen for 304,000 square feet to relocate its headquarters to BioMed's Emeryville Center of Innovation in the Bay Area. Learn More

Thermo Fisher Scientific has opened a $90 million, 50,000-square-foot viral vector manufacturing facility in Lexington, Massachusetts. The contract development and manufacturing organization expects to create more than 200 jobs at the site, which will support development, testing and manufacturing for viral vectors, the inactivated viruses used to deliver gene therapies. According to the company the new site will help address a "bottleneck" in manufacturing viral vectors. Alert readers will recall that Thermo Fisher paid $1.7 billion earlier this year for viral vector contract manufacturer Brammer Bio. Learn More

Eli Lilly and Company this week unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise. With over 65,000 square feet of space, Lilly Gateway Labs offers 32 state-of-the-art, flexibly designed private lab modules. Each module includes lab space for six to eight scientists, office space, and workstations. Learn More

Singapore has announced that its research and development hub Biopolis will be expanded to meet the needs of biotechnology start-ups. Phase 6 of Biopolis will add a further 376,000+ sq. ft. (35,000 sq m) of business park space for biomedical sciences research and supporting activities and 64,000+ sq. ft. (6,000 sq m) for office and retail use. This will include 21,000+ sq. ft. (2,000 sq m) of fitted-out laboratory spaces with lab benches, waste drainage and exhaust provisions. Biopolis currently houses nine A*Star research institutes and over 60 companies, with thousands of employees undertaking research, clinical trials and commercialization of new scientific discoveries. Learn More

Novartis has opened a new manufacturing facility for cell and gene therapies in Switzerland. In addition to manufacturing areas for novel CAR-T cell therapies, the new building also hosts the production of innovative, difficult-to-manufacture solid dosage forms such as tablets and capsules. In September 2019, the first clinical production of a cell and gene therapy batch was successfully completed. The $90 million facility is on track to begin commercial production of its cell therapy Kymriah for cancer in 2020. The Swiss facility, as well as a separate French site also being expanded, are central to Novartis's plans to transform Kymriah from a modest $250 million-per-year seller into a $1 billion blockbuster as European demand rises. Learn More

Plans are moving forward for another Bay Area biotech campus. Alexandria Real Estate Equities is transforming a chunk of property in San Carlos, California into a 1.6 million-square-foot biotech campus. According to the San Francisco Business Times, the real estate development company submitted plans for its proposed biotech campus. Alexandria Real Estate Equities intends to turn the space into six new buildings, each about five to seven floors for biotech companies to use. In addition to the buildings, the site will also include an amenities structure, parking garages and a small park, according to the Business Times. Learn More

Horizon Therapeutics has announced the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development and other R&D functions. Horizon plans to add new positions in bioanalysis, clinical research, pharmacology, manufacturing and business development during the next year. Learn More

Maravai LifeSciences has unveiled its new $40 million headquarters this week in San Diego, California. In addition to doubling overall manufacturing capacity by adding a 50,000 sq. ft. manufacturing facility, TriLink BioTechnologies, a Maravai LifeSciences company  whose headquarters will also be housed in the new facility, has added five new Current Good Manufacturing Practice (cGMP) suites, for a total of six, that can be specifically tailored for customer drug development campaigns including scaleup for Phase I clinical trials. The new 105,000-square-foot facility houses the company's current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing employees. Learn More

Eli Lilly and Co. will invest $400 million in its manufacturing facility in Indianapolis, an upgrade that will lead to an additional 100 highly skilled jobs at the Indianapolis-based drug manufacturer. The money will go to enhancing the existing facilities at the Lilly Technology Center campus, which manufactures insulin. It will also help Lilly increase its capacity to make other diabetes medicine, company officials said in a news release. In addition to insulin, Lilly makes 10 non-insulin diabetes drugs. Company officials said that the money announced this week would go to improving the company's syringe-filling, device assembly and packaging operations. Learn More

Arkuda Therapeutics, a biotechnology company developing therapies to change the trajectory of neurodegenerative disease, has signed a 10,819 square foot lease at Arsenal Yards' new state-of-the-art life science lab space. The biotech becomes the latest in a growing number of emerging biopharma companies to relocate from Kendall Square in Cambridge to Watertown's biotech cluster. Arsenal Yards boasts more than one million square feet of development including lab and office space. Learn More

Fujifilm Diosynth Biotechnologies has announced the expansion of its gene therapy services with the addition of dedicated process and analytical development laboratories. As part of a capital investment of approximately $120 million in the gene therapy field by FUJIFILM Corporation, an investment of approximately $55 million USD will be made to establish a new Gene Therapy Innovation Center adjacent to the existing state-of-the-art cGMP gene therapy manufacturing facility in College Station, Texas. The Gene Therapy Innovation Center will be approximately 60,000 square feet and house state-of-the-art upstream, downstream and analytical development technologies. The facility will be operational in the fall of 2021. Learn More

CMO CMIC has leased 233,000 sq. ft. at 270 Prospect Plains Rd. in Cranbury, NJ. The site will be used for office, research and development, production, packaging, manufacturing, warehousing and distribution. The deal involved negotiating a lease termination with an existing tenant, Sun Pharmaceutical, and arranging for the purchase of in-place research and development infrastructure. Learn More

Rentschler Biopharma is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a 500L single-use bioreactor for the 93,000 square foot facility near Boston, MA. The XDR-500 bioreactor, with a working volume of 100-500 L, is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Learn More

Takeda this week opened a new plant in Singen, Germany that will manufacture the company's experimental dengue vaccine, which is newly supported by Phase 3 results that appear to show the shot is effective in guarding against the mosquito-borne viral disease. The biopharma has invested more than $140 million over the past three years as it built the facility, which will employ as many as 200 people once operational. Takeda first began construction in 2016, and the plant is now ready for packaging production. End-to-end production of the vaccine, known as TAK-003, will be ready nearer to when Takeda expects to secure licensure of the drug. Learn More

AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The biopharma giant has also set up a $1 billion fund to foster biotech innovation in that country. The move will see the AstraZeneca found a global R&D center in Shanghai's central Jing'an district. The company currently operates R&D centers at its Cambridge, UK, headquarters as well as at sites in Maryland and Sweden. The new China facility will carry out R&D for innovative drugs, with the focus being on diseases that are prevalent in China. The site will bring AstraZeneca's R&D headcount in China to 1,000 people. The industry leaders says it has no plans to co-locate all China R&D facilities. Learn More

Azurity Pharma, formed in May has picked 8 Cabot Road in Woburn for its new expanded corporate headquarters. The company will relocate from Presidential Way to 14,627 square feet within the 60,000-square-foot 8 Cabot Road office building. Azurity specializes in drug delivery systems including ones optimized for children and the elderly. The company was formed in May when CutisPharma acquired Silvergate Pharmaceuticals and rebranded the combined company. Along with the Woburn headquarters, Azurity has a manufacturing facility in Wilmington. Learn More

San Diego will create California's first "capacity bank" for water and sewer, allowing breweries and biotech firms to cheaply buy excess water and sewer capacity from former factories. The City Council unanimously approved the capacity bank, calling it an innovative idea that will create jobs and help the city avoid expensive expansions of its sewer and water infrastructure. The council also unanimously approved a companion proposal that geographically expands and softens the qualifications for the city's "guaranteed water" program, which ensures local firms access to water during droughts or other kinds of shortages. Learn More

Prelude Therapeutics, one of the biotech companies growing up in the state-backed Delaware Innovation Space at the DuPont Experimental Station just outside Wilmington, has pledged to hire up to 49 biotech professionals and find larger quarters in the state, to win a commitment for taxpayer financing. Founded in 2016, Prelude plans to invest $5 million in its new headquarters, state officials said in a statement. The state-funded Council on Development Finance has agreed to give Prelude $830,000 in Delaware Strategic Fund grants, based on the company's meeting its hiring goals to boost its current 32 workers to 81 over the next three years, including scientists and "skilled associates." Learn More

Teesside University in the United Kingdom has officially opened its $28 million National Horizons Centre, which it believes will catalyze talent development and increase engagement between research, teaching and industry. The university already has collaborative partnerships with companies such as Fujifilm Diosynth Biotechnologies and GlaxoSmithKline, which officials say will ensure a foundation for the development of industry-relevant training and work-ready graduates. Among the new equipment featured at the state of the art center are glass and steel bioreactors and bioreactor controllers from Applikon. Learn More

WuXi Biologics plans to build a four-storey vaccine manufacturing plant which will bring a further 200 jobs to Dundalk, Ireland. WuXi has already commenced building a $360 million factory on their Mullagharlin Road site in Dundalk. A new company called WuXi Vaccines Ireland submitted the plans for an additional 167,000 sq. ft. of new buildings to Louth County Council, to be built to the north of the site adjacent to the Mullaharlin Road, earlier this month. The newly-proposed facility will comprise of one main integrated administration, manufacturing and warehouse building with some ancillary buildings. Learn More

Anpac Bio has signed a 10-year lease on a newly constructed 6,724-square-foot office at the Spring House Innovation Park in Pennsylvania. The company, founded in 2008, had been looking to expand to the East Coast. Anpac, which will keep its office in San Jose, will bring 10 of its 100 employees to the Spring House complex in the spring. Alert readers mights recognize the name of the industrial park, it is home to a number of other biopharma industry suppliers and end users including Chromatan. Learn More

TriPharm Services, a new CDMO, is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment. The facility, located at 627 Davis Drive in Morrisville, NC, and totaling 32,000 square feet, will offer four isolator filling suites and the highest level of control available for Grade A processing of client biologic and small molecule products. Featuring state-of-the-art equipment, the facility has eight multi-purpose cleanrooms to support manufacturing operations, along with modern, specialized utility systems to scale to client requirements. The state-of-the-art equipment and facility are set to be fully operable in the second quarter of 2020. Learn More

Sanofi this week unveiled a roughly 100,000-square-foot biologics manufacturing plant in Framingham, Massachusetts, touting the facility as a key cog in a broader plan to retool its production base.  The new site will use continuous manufacturing rather than traditional batch processing, a change the industry has generally been reluctant to make. Relying on single-use equipment, the plant will use less energy and chemicals, executives said, while boosting productivity versus a typical set-up. Sanofi has spent about $320 million over the past five years on the Framingham facility. The plant is expect to be approved by the FDA late next year. Learn More

The Delft University of Technology in the Netherlands has launched Planet B.io, an incubator aimed at scaling up technology developed by industrial biotech startups. Planet B.io is based at the campus of the Delft University of Technology and contains a total of 32,000 sq. ft. of office and lab space for small biotech companies. To help startups scale up, there is a shared pilot production facility where companies can test their technology with the help of industrial mentors. The incubator is just one of a few that are focusing exclusively on industrial biotech, which can have different requirements such as large-scale bioreactors and fermentation tanks. Learn More

The University of Maryland BioPark and developer Wexford Science & Technology have revealed updated plans to the Baltimore City Planning Department's Urban Design & Architecture Advisory Panel (UDAAP) for a $200-plus million, 10-story, 333,000 sq. ft. office and biotech building at the northwest corner of Martin Luther King Blvd. and W. Baltimore St. in South Baltimore, Maryland. The new building, which is being called 4 MLK, is Phase One of a two-phrase project that will redevelop a Poppleton/Hollins Market block that borders Martin Luther King Blvd., W. Baltimore St., W. Fayette St., and N. Fremont Ave. Learn More

Sanofi has opened a new UK Headquarters, based at Thames Valley Park in Reading, Berkshire. The new 70,000 square ft. office facility marks a $45 million investment to Reading and will be the new base for 500 of the 1,200 Sanofi employees in the UK. The company revealed that it is actively seeking to recruit at least 50 new roles in the coming months, in addition to ten graduate students via its new Aspiring Leaders program. The company welcomed Matt Hancock, secretary of state for health and social care, to open the "state of the art" facility, alongside Paul Hudson, chief executive officer of Sanofi and Hugo Fry, UK's managing director. Learn More

With pastel-coloured walls, neon decorations and plush sofas, a co-working space in Biopolis can be mistaken for a cafe or a blogshop's retail outlet. But NSG BioLabs, fitted with a sterile lab and high-tech equipment, is a 15,000 sq ft co-working space for biotech start-ups. To be launched next month, it looks set to play host to some of the nation's brightest minds. The facility will be an incubator for small biotech start-ups, ranging from those with just one to two researchers to those with 20 to 30 people. It has 120 desks, 96 lab benches, eight office suites and six meeting rooms. Its founder, 36-year-old Daphne Teo, decided to set up the premises after the biotech company she co-founded struggled to find a space to operate in. Learn More

Janssen this week officially opened its new manufacturing building in Ringaskiddy, Co. Cork. The company has operated a biopharmaceutical supply chain facility in Ringaskiddy since 2005. The expansion of the roughly 100-acre biomanufacturing site increases the company's production capacity by an additional 205,000 sq. ft. and creates 200 new full-time jobs. Approximately 450 people were employed on-site during the two-year construction project. Learn More

GSK has officially opened a new biologics manufacturing plant at its existing site in Rockville, Maryland. The $139 million facility was built to add manufacturing capacity for GSK's Benlysta, to that end it features an additional 2 x 10,000L of capacity. The scope of the project included the demolition of existing suites and the engineering, installation and validation of new equipment. The unveiling of the Maryland site comes just about a week after GSK officially opened a new $120M in biopharma plant at the drugmaker's manufacturing site in Upper Merion, Pennsylvania, just outside of Philadelphia. Learn More

Cellectis will tap Lonza to manufacture its experimental CAR-T cell therapies for blood cancers, in an effort to expand its product supply for clinical studies. Lonza will produce the therapies at its facility in Geleen, Netherlands. Before signing the deal with Lonza, Cellectis announced plans in March for in-house manufacturing sites in Raleigh, North Carolina and Paris, France. Together the two facilities currently under construction will give Cellectis nearly 100,000 square feet of manufacturing space for both commercial and clinical use. No financial details of the deal were disclosed by the companies. Learn More

LabCentral, the biotech incubator at 700 Main Street in Cambridge, MA, that has nurtured dozens of startups in a shared working space since 2013, plans to roughly double in size in two years with a new 100,000-square-foot facility in the heart of Kendall Square. But instead of providing laboratory equipment for scientists to do early-stage research, the new outpost will help startups that have cleared that hurdle to develop potential drugs that the firms eventually hope to test in clinical trials. This comes after the local government announced a $5 million grant to LabCentral. Learn More

New York City's life sciences community continues to boom as Deerfield Management Company, in partnership with LifeSci NYC and the New York City Economic Development Corporation, have announced an initial $635 million investment to create a transformative life sciences campus in the Big Apple, and a total commitment of $2 billion by 2030. The home for the future campus is a facility on Park Avenue that provides more than 300,000 square feet of space, of which more than 200,000 square-feet will be wet lab capable, to support healthcare and biotech start-ups and growing companies that work on cutting-edge R&D to treat diseases and chronic conditions. The campus is expected to open in early 2021. Learn More

GSK has announced a $120 million investment to expand its manufacturing facility in Upper Merion, Pennsylvania. The newly outfitted manufacturing space is made to be more flexible through the use of single-use bioreactors and disposable bioprocessing components. A new analytical lab is also part of the facility, and the processes associated with quality and commercial testing have been streamlined to ensure medicines are ready for patient use as soon as possible. By bringing together the R&D and manufacturing teams in one facility in Upper Merion, GSK plans to achieve increased synergy and efficiency. Learn More

JLL has announced it recently completed a lease for 185,000 square feet of space at the 433-acre Bristol-Myers Squibb Hopewell campus with PTC Therapeutics. Located at 311 Pennington-Rocky Hill Road in Hopewell, the property includes an existing state-of-the-art biologics production facility, and supporting research and operations buildings. PTC Therapeutics' long-term lease will occupy Buildings 9, 10, 12, 13 and a portion of Building 18 at the Princeton West campus. PTC plans to further develop the biologics facility to support gene therapy production, and foster innovation and employment in the community. Learn More

Pfizer has paid about $19 million for the land and building near the intersection of I-40 and I-540 in Durham, North Carolina where it will consolidate its clinical gene therapy production. It will start construction on retrofitting it next year and expects to complete the work in 2022, at about the same time the lease expires on its current clinical supply facility in Chapel Hill. Pfizer acquired that facility via its 2016 Bamboo Therapeutics deal.  The new operation in Durham, called the Advanced Therapy Medicinal Product (ATMP) facility, will double Pfizer's clinical manufacturing capacity in gene therapy and will include two drug substance suites, a single drug product suite and labs. Learn More

WuXi Diagnostics, a one-year-old joint venture between New WuXi Life Science Investment Limited and Mayo Clinic, has confirmed that it plans to open a "research and diagnostic testing development facility" in downtown Rochester, Minnesota ... "to accelerate esoteric diagnostic product development, and bring more personalized and accurate clinical diagnosis services for global patients." The new facility will be located on the third floor of the new One Discovery Square complex on the corner of Fourth Street and Second Avenue Southwest. This follows a WuXi Diagnostics building permit filed in Rochester in April for a $543,000 tenant space project. Learn More

All employees at the Irish manufacturing arm of biopharma giant Roche in Co Clare Ireland will be made redundant by next June. Some 132 workers were employed at the Clarecastle plant at the end of last year and the directors state that decommissioning works will commence next year and continue to 2023. Roche originally announced in 2016 that it was to close the plant at Clarecastle after it failed to secure a buyer for the site. The facility is currently in the process of a phased closure and the directors state this will be complete by mid-March 2020. Learn More

Activation Capital, a nonprofit affiliated with the 34-acre VA Bio+Tech Park, has filed plans with the city of Richmond to build a six-story, 100,000-square-foot research building at 706 E. Leigh St. The building will occupy a roughly 2-acre block bounded by East Jackson, East Leigh, North Seventh and North Eighth Streets. Plans also show a 740-space parking deck. The project  awaits city approval. The property is already zoned with the same designation as other properties in the park, meaning it likely won't require a rezoning or special-use permit. Learn More

Backed by venture capital firm Pillar, Petri has a three-year $15 million commitment to back companies developing new biotech applications, along with the enabling technologies to bring these products to market. Pillar has already invested in a couple of companies that show the potential promise of new biotech research coming from Boston-based universities, like Boston University, Harvard and the Massachusetts Institute of Technology. Over time, the accelerator expects to have 10 to 20 companies in each market segment as the program expands. In addition to checks of at least $250,000 the Petri accelerator has lab and office space available for each company. Learn More

Pfizer has made public plans to establish a digital research hub with a focus on artificial intelligence and big data analytics in Thessaloniki, Greece. The Thessaloniki hub is part of a planned multinational network of digital research centers to develop technology that can be incorporated into Pfizer's development pipeline of medicines and vaccines. The biopharma giant expects the facility, the first of six, to become operational in 2020, providing up to 200 jobs. The recent announcement comes as a surprise to some due to the lack of biopharma on the island nation. However, Pfizer CEO Albert Bourla is a native of Greece, specifically Thessaloniki, Greece. Learn More

An India-based subsidiary of Sanofi said it will sell a manufacturing plant in Ankleshwar, Gujarat, to Advent International's Zentiva for about $37 million. The site is Sanofi's oldest manufacturing facility in India and produces medications including Combiflam, Allegra and Amaryl. Production of those products will be moved to other sites including in Goa, according to a Sept. 11th Sanofi release posted to India's stock exchange. The agreement builds on a much larger deal from last year, when Advent paid $2.1 billion, for Sanofi's European generics business, Zentiva. Now, a Zentiva unit in India is taking over the Ankleshwar site, which manufactures more than 6 billion tablets a year. Learn More

The Rock Creek Property Group has secured a $34 million loan for the conversion of a former manufacturing facility in Gaithersburg, Md., into a life science property. The property, built in 1973, sits on a 13-acre plot and will be converted into a 120,000 sq. ft. Class A life science building outfitted for one tenant. Rock Creek purchased the former manufacturing facility - at 700 Quince Orchard Road in Gaithersburg - from DRS Solutions in 2015 for just $5 million. The speculative conversion will establish the first floor of the building as a parking garage, and the build out and business plan will aim to house just one tenant, although it "breaks nicely from two to four ," Learn More

The UC Santa Cruz Genomics Institute is moving off campus and into the middle of a growing biotech hub on the city's westside. In a new 11,000-square-foot headquarters in a renovated office building at 2300 Delaware Ave., the Genomics Institute is hoping to find firm footing for its work in Santa Cruz's growing biotech corridor. Biotech incubator Startup Sandbox, a university-affiliated nonprofit, is just blocks away on Natural Bridges Drive. Budding biotech startups Claret Bioscience, NantOmics and Ontera are just around the corner. Prior to this summer, the institute was spread out across five sites on the sprawling university campus. Learn More

Morgan Sindall Construction has won a $23 million contract to build a new headquarters for Eli Lilly and Company in Basingstoke, UK. Located within the Basing View Enterprise Zone, the 45,000 sq ft five-story commercial building will provide Grade A workspace and a new home to the biopharma giant. The main contractor is carrying out the work for Basingstoke and Deane Borough Council, and Morgan Sindall Group sister company, Muse Developments. Designed by architect TP Bennett, the building will be owned by the borough council and will be the second-largest commercial asset in its portfolio. Learn More

The Westchester County Industrial Development Authority has given preliminary approval for a tax exemption on a $38.2 million biotech project in Ardsley, New York. BioMed Realty plans to complete two shell buildings at 430-440 Saw Mill River Road, next to the Accorda Therapeutics labs and offices on its Ardsley Park campus. The developer says it is targeting small life science companies that cannot afford the costs of outfitting expensive labs. To that end, BioMed is willing to lease as little as 5,000 square feet to smaller enterprises. The vacant structures in Ardsley contain a total of 97,000 square feet. Learn More

In May, Thomas Jefferson University opened the doors to a Philadelphia first - the Jefferson Institute for Bioprocessing (JIB). With the potential to help fill the local workforce gap, JIB is the only bioprocessing training institute in the country where students can engage in a range of workshops, training and academic programs modeled after the National Institute for Bioprocessing Research and Training (NIBRT) curriculum. Located in Spring House Innovation Park in Lower Gwynedd, Pennsylvania, the JIB gives scientists, engineers and technicians access to a state-of-the-art bioprocessing training facility where they can practice complex bioprocessing procedures using industry-grade equipment. Learn More

Strides Pharma this week announced that it has acquired a drug manufacturing facility in Riviera Beach, Florida from Micelle BioPharma. The financial details of the deal have Strides paying $500K for the facility and planning to invest upwards of $10 million to expand the sites capabilities. According to published reports, the manufacturing facility has undergone multiple inspections by the U.S. FDA over the years and has no outstanding observations. It joins eight other formulation sites distributed globally that are operated by Strides. Learn More

As it closes in on one of the most valuable land deals in Seattle history, Alexandria Real Estate Equities is betting that biotech can thrive in a real estate market dominated by big tech. The real estate firm recently reached an agreement with the city of Seattle to buy the Mercer Mega Block, a trio of development sites that lie between Amazon's campus and the cluster of life sciences institutions around Lake Union. It's the latest in a long line of bets made by Alexandria on Seattle's life science industry. Alexandria plans to pay $143.5 million for the site, roughly 40 percent above the original bid. Learn More

Pfizer is investing $500 million to expand its manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy. The investment will add additional capacity and capabilities to a facility that makes some of Pfizer's most closely watched experimental treatments. The Sanford plant manufactures therapies used for the company's late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies. It is also responsible for making components for some of Pfizer's vaccines, such as Prevenar 13, which had nearly $6 billion in sales in 2018. Learn More

Caris Life Sciences has unveiled plans to develop the Caris Life Sciences Corporate Park in Irving, Texas, adding to the company's growing footprint in the United States. This new facility will enable approximately 115,000 square feet of new R&D laboratory and office space, and create more than 500 new job opportunities. Within the new Caris Life Sciences Park, employees will work to substantially expand the company's blood-based diagnostic assays as well as blood-based molecular profiling and increase research and development capacity. Learn More

Biopharma will officially open its new blood fractionation facility near the Ukrainian city of Kiev next month. The construction of the site, and subsequent commissioning, took roughly four years to complete and cost $75 million. The plant utilizes industry leading bioprocess solutions from Stilmas, Olsa, GEA Westfalia, General Electric, Pall, and Steriline.  According to published reports, the facility will have three lines for the production of albumin, immunoglobulin, and factor VIII. The processing capacity ranges from 250,000 to one million liters of plasma per year. Learn More

The Colorado Economic Development Commission agreed this week to offer up to $24.8 million in tax and other incentives in hopes of persuading an unnamed biotech company to open a campus in Boulder County and create 1,000 well-paid jobs. According to reports the unidentified company already operates at four sites in Colorado, but if it accepts Colorado's tax credit offer it would consolidate in Boulder County. Estimates value the project at upwards of $130 million. However, other states are being considered as potential locations for the site including Minnesota, Tennessee and Texas. Learn More

Regeneron is planning to build a four-story, 256,000+ sq. ft. structure known as the Science Building at its Tempel Lane campus in Albany, New York. The building, which will house both labs and offices, would be the third and final phase of expansion at Regeneron's campus. The project will be managed by the Boston office of the engineering and construction firm Jacobs. Alert readers will recall that Regeneron has been investing heavily into its Albany site. This includes construction of a 212,000 sq. ft. warehouse and the ongoing project to build a 346,000 sq. ft. manufacturing facility at the site. This latest project is expected to take 30-36 months to complete. Learn More

Aldevron has been granted the $5 million tax break it sought to help facilitate the expansion of its existing facility and the building of a new facility. Specifically, the building of a new, state-of-the-art, 180,000 square foot biologics manufacturing facility and a 20,000 square foot expansion of their existing facility in Fargo, North Dakota. According to published reports, the estimated budget for the project is $72 million, which includes both construction of the buildings as well as procurement of associated equipment. This is a big win for Fargo which faced competition from others seeking to be the site of Aldevon's new facility. Learn More

Cambridge, Massachusetts-based Brammer Bio is planning to set up a new manufacturing facility in Norton, Massachusetts. The Thermo Fisher subsidiary plans to employ 300 staff in its new Norton plant by 2021. While the project is still in the preliminary stages, the cell and gene therapy firm plans to fund the new plant with tax increment financing (TIF), a public financing method used for redevelopment. Brammer currently employs around 600 people in various locations, so will be increasing its staff by 50%. Learn More